CVS Executive to Provide Perspective on Kidney Care

Bruce Culleton, MD, will be one of the co-presenters at a plenary session on “Perspectives on Innovation and Transformation in Kidney Care” on Saturday, Nov. 9.

Bruce Culleton, MD

/kidneynews/11_10_11/34a/graphic/34af1.jpg


Dr. Culleton is vice president and chief medical officer of CVS Kidney Care, a subsidiary of CVS Health. In that position, he provides medical oversight and guidance to all strategic initiatives for CVS Kidney Care.

In 2018, CVS Health announced a new initiative focused on CKD and dialysis, built on the company’s focus on driving innovation in the management of chronic disease to help improve patient health outcomes while managing costs. The program focuses on early identification of kidney disease and expansion of home dialysis in order to optimize care for patients with CKD. The company plans to introduce innovative home hemodialysis technology.

“While in-center dialysis clinics are currently the most common choice for hemodialysis treatment, published clinical research has shown improved cardiac health, metabolic control, and survival for patients who are treated with longer, more frequent dialysis treatments. This treatment paradigm is best delivered in the convenience of a patient’s home,” Dr. Culleton said. “CVS Health is uniquely positioned to build a solution that will enable us to identify and intervene earlier with patients to optimize the management of chronic kidney disease, while at the same time making home dialysis therapies a real option for more patients.”

Prior to joining CVS Health in 2017, Dr. Culleton spent more than 10 years in the medical device industry. He was vice president of global clinical development at Becton Dickinson for two years and vice president of renal global medical affairs at Baxter Healthcare from 2007 to 2016.

Before joining industry, Dr. Culleton was an academic nephrologist at the University of Calgary in Alberta, Canada, where his research interests included CKD epidemiology and home hemodialysis. During that time, he published more than 100 scientific papers related to CKD, dialysis, and clinical practice guidelines.

Dr. Culleton received his medical degree from Memorial University of Newfoundland, Canada, and completed fellowships in internal medicine and nephrology at the Royal College of Canada as well as in clinical epidemiology at Boston University. He also received an MBA from Northwestern University’s Kellogg School of Business in Evanston, Ill.

October/November 2019 (Vol. 11, Number 10 & 11)